You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NPR reports that the first person in the US to undergo a CRISPR-based treatment for sickle-cell disease continues to do well nearly a year after treatment.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.
Doctors in the US have used CRISPR gene editing to try to treat a woman with sickle cell disease as part of a clinical trial, according to Popular Science.
US companies have begun recruiting for a CRISPR-based gene-editing trial to treat β-thalassemia, Stat News reports.
The Telegraph reports that UK regulators gave CRISPR Therapeutics the go-ahead for its beta thalassemia clinical trial.
Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.
The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
CRISPR Therapeutics is moving toward clinical trials for beta thalassemia and sickle cell disease treatments, according to Wired.
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.
Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.
CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.
In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.